The combined company will focus on developing treatments for hepatitis B virus, a major global health problem, while also pursuing Tekmira’s other product candidates. The transaction brings together the companies’ broad expertise in antiviral drug development. A multi-office Dorsey team served as U.S. legal advisor to Tekmira in this transaction.
Tekmira and OnCore merge to create global company focused on HBV treatment
Our client, Tekmira Pharmaceuticals, a leading developer of RNA interference therapeutics based in Canada, and Pennsylvania-based OnCore Biopharma merged in a transaction that will allow both companies’ shareholders to participate equally in the combination’s prospects.